Document is current
Any future updates will be listed below
-
Authors
Hu, Wei https://orcid.org/0000-0002-0392-6939
Dolsten, Gabriel A.
Wang, Eric Y. https://orcid.org/0000-0002-6120-5136
Beroshvili, Giorgi
Wang, Zhong-Min
Ghelani, Aazam P.
Uhl, Lion F. K.
Bou-Puerto, Regina https://orcid.org/0000-0002-7546-3312
Huang, Xiao
Michaels, Anthony J.
Hoyos, Beatrice E.
Jin, Wenjie https://orcid.org/0000-0002-7527-6357
Pritykin, Yuri https://orcid.org/0000-0001-6589-981X
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA008748)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI034206, DP2AI171161)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 3 September 2025
First Online: 8 October 2025
Competing interests
: A.Y.R. is a Scientific Advisory Board member and has equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus BioSciences, Santa Ana Bio, Odyssey Therapeutics, Nilo Therapeutics and Vedanta Biosciences; he is also a Scientific Advisory Board member of BioInvent and Amgen and a co-inventor of a CCR8+ Treg cell depletion IP licensed to Takeda, which is unrelated to the content of this publication. Z.-M.W. is an employee of Genentech, which is unrelated to the content of this publication. The other authors declare no competing interests.
